The eighth annual pharmaceutical innovation study by the Deloitte Centre for Health Solutions looks at the state of R&D in the biopharma industry and estimates the return on investment that 12 large cap biopharma companies may expect to achieve. The report also includes an extension cohort of four mid-tier biopharma companies. Click here for link to full report. #RD #pharmaceuticals #Deloitte #oncologyresearch
Recent article from Oncology Practice Management highlights the challenges oncologist face each day as they try to prioritize patient care. According to a study reported in the Annals of Internal Medicine, physicians only spend approximately 27% of their time with patients (Sinsky C, et al. Ann Intern Med. 2016;165:753-760). For every hour spent with patients, 2 additional hours are spent on the EHR and completing desk work, with an additional 1 to 2 hours of personal time ea
"A new analysis finds that certain genes people are born with may play a critical role in whether or not checkpoint inhibitors will work. For some people with cancer, immunotherapy drugs called checkpoint inhibitors, which take the brakes off the immune system and allow it to attack cancer cells, have been a game changer. They can shrink even very advanced cancersto levels that can no longer be detected. But for most patients, these drugs have been disappointing. Researchers
Merck will spend an estimated $12.5 million on TV ad spend on the 'It's TRU: Donna's Story - Living Longer Is Possible' ad. This brings it to number 8 on the top 10 list and only oncology ad on the list, according to Fierce Pharma See full list here. See full television ad by clicking here.
"The PARP inhibitor market is going to be split. The question is to what extent, and whether insurers, pharmacy benefit managers and other payers will use this crowding to lever down drug prices." - from Bloomberg article by Max Nisen Click here for full article. #PARPinhibitors #breastcancer #ovariancancer
Cancer Research Institute publishes analysis in Annals of Oncology 2017 "Advances in immuno-oncology (IO) are revolutionizing the standard of care for many types of cancer." "26 immunotherapies have been approved, and 17 types of cancer have at least one approved im- munotherapy as a treatment option." "It is probably the best time for progress in oncology in the past decades."
Oncology Drugs Approved in 2017 thru Dec 8th Aliqopa (copanlisib); Bayer; For the treatment of follicular lymphoma , Approved September 2017 Alunbrig (brigatinib); Ariad Pharmaceuticals; For the treatment of advanced ALK-positive metastatic non-small cell lung cancer, Approved April 2017 Bavencio (avelumab) ; EMD Serono/Pfizer; For the treatment of Merkel cell carcinoma , Approved March 2017 Besponsa (inotuzumab ozogamicin); Pfizer; For the treatment of adults with relapsed o
In 1988, when I first managed a sales territory, the role of the representative was highly valued. A career as a pharmaceutical representative was a prized position. I think it is still today. However, it is a role that is changing with the times. Check out this Eye for Pharma white paper on the new data driven rep. Click here to access